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Purpose: Compare patient adherence to glaucoma therapy with morning versus evening dosing 
schedules.
Methods: Retrospective chart review of 41 consecutive patients who had used the Travatan™ 
Dosing Aid (Alcon, Fort Worth, TX). Patients had been nonrandomly assigned morning or 
evening dosing at initiation of usage. Dosing aid data was recorded and analyzed using paired 
student t-tests where appropriate. Adherence was deﬁ  ned as the dose being administered within 
3 hours of the prescribed dosing time.
Results: Records of 18 patients in the morning group and 23 in the evening group were re-
viewed. Average time of use was 51.06 ± 4.94 days for the morning group and 50.65 ± 5.38 
days for the evening group (p = 0.80). Patients taking the morning dose were less likely to 
miss an entire day of dosing (days missed in morning group = 3.33 ± 1.33; evening group 
= 5.87 ± 1.52, p < 0.001). The overall adherence rate was not statistically different between 
groups (morning group = 82.72 ± 7.32%; evening group = 78.96 ± 6.12%, p = 0.08) although 
the morning group tended to be more adherent to therapy. Patients in the morning group were 
also more likely to take their drops later rather than miss the entire day’s dose.
Conclusions: The rate of adherence for both the morning and evening dosing groups was better 
than previously reported. Dosing drops in the morning, rather than in the evening, may lead to 
fewer entirely missed days of glaucoma eye drop therapy.
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Introduction
Primary open-angle glaucoma (POAG) is a leading cause of blindness worldwide 
(Quigley 1996; Goldberg 2000). Current therapy relies heavily on patient cooperation 
in self-administration of drops that decrease intraocular pressure (Tsai and Kanner 
2005). It is widely accepted that patient compliance and adherence with prescribed 
medical regimens can often be suboptimal. Nonadherence to therapy can be secondary 
to patient failure to take medications, missing dosages, inability to instill drops, failure 
to persist with usage as well as many other factors (Schartz 2005). Several studies have 
addressed the issue of adhering to prescribed dosing regimens and report nonadherence 
rates ranging from 24% to 59% (Gurwitz et al 1993; Patel and Spaeth 1995; Rotchford 
and Murphy 1998; Tsai et al 2003; Schwartz 2005). Further complicating this problem, 
many patients self-report adherence at much higher levels than studies suggest. This 
can lead to disconnect between what the physician might believe is happening and 
what the patient is actually practicing at home (Kass et al 1986).
There have been multiple studies attempting to quantify patient adherence with 
glaucoma medication use. Self report, dosing aids, and microchips attached to eye 
drop bottles have all been used (Kass et al 1984; Rivers 1992). Each technique has its 
own positive and negative attributes with self-reporting relying on patient memory/Clinical Ophthalmology 2007:1(1) 80
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perception and electronic devices assumed to be fail-proof. 
Recently, a new electronic dosing aid was introduced which 
acts as both a dosing monitor as well as compliance aid 
(Boden et al 2006). The TravatanTM Dosing Aid (TDA) 
(Alcon, Fort Worth, TX) is a portable electronic device 
speciﬁ  cally designed to assist patients in dosing travoprost 
(Travatan®, Alcon).
Each TDA is preprogrammed with patient information, 
preferred dosing time, and reminder prompts that can be specif-
ically altered by the prescribing physician for certain times of 
the day depending on patient needs and daily habits. The device 
also records the number and times the drop administration 
lever is depressed as a patient instills travoprost. In this study 
we use the TDA device to investigate the effect of dosing time 
on patient adherence to glaucoma therapy.
Methods
This was a retrospective nonrandomized consecutive case 
series of patients placed on glaucoma monotherapy using the 
TDA. Institutional Review Board approval was obtained for 
this retrospective review. Forty-one total participants who 
had been given the TDA were identiﬁ  ed and data was col-
lected from each device for review. Demographic informa-
tion regarding age and diagnosis was also collected.
Patients had been assigned to administer their once daily 
medication either in the morning (5–10 am) or the evening 
(6–11 pm) based on their own preference. The dosing regi-
men for each patient consisted solely of one drop of travo-
prost in each treated eye administered either in the morning 
(18 patients) or at night (23 patients). 
In this study, nonadherence as determined by the dosing 
device was deﬁ  ned in multiple ways. Days on which the 
patient completely failed to take the medication, failed to 
take the medication within the preprogrammed time frame 
(three hours before or after the designated dosing time), or 
over-medicated were considered nonadherent days. The TDA 
automatically marks a failure to take the medication as failure 
to adhere. Taking the medication outside the designated time 
frame is also noted as a nonadherence event and marked with 
a star on the printout (Figure 1). Multiple dosing events on 
the same day could still be marked as adherent as long as one 
drop is taken at the designated time. Days missed are marked 
as a ‘zero’ on the TDA print out and are easily identiﬁ  able as 
dosing failures. The percentage of days in which the patient 
adhered to the regimen was recorded and compared between 
the two groups. Statistical analysis using paired t-tests was 
performed.
Results
The mean age for each group, morning (66.94 ± 9.36) and 
evening (69.52 ± 8.72) was similar (p = 0.88). There were 
16 POAG patients and two low-tension glaucoma (LTG) in 
the morning group and 17 POAG, three LTG, one congenital 
glaucoma, and two inﬂ  ammatory glaucoma patients in the 
evening group. The duration of TDA usage was similar for 
the morning group (51.06 ± 4.94 days) and the evening group 
(50.65 ± 5.38 days). The differences were not statistically 
signiﬁ  cant (p = 0.80).
Patients who were taking the morning dose were less 
likely than the evening dosing patients to miss an entire day 
of dosing (Figure 2) and this difference was statistically 
signiﬁ  cant (p < 0.001). The percent adherence, on the other 
hand, which included both dosing misses or an improper 
dosing event was higher for morning patients compared with 
evening patients (Figure 3). However, this difference was not 
statistically signiﬁ  cant between the two groups (p = 0.08).
Patients in the morning group were more likely to take 
their drops past the 3-hour dosing window preprogrammed 
into the TDA rather than miss a dose entirely. The majority 
(70%) of patients in the morning group who missed the 3-hour 
dosing window took their drops within 6 hours of the dosing 
period while the remainder did not to take their drops on that 
given day. Twenty-eight percent of patients in the morning 
group and 35% of patients in the evening group appeared to 
over-medicate on the day of or night prior to clinical examina-
tion (Figure 4). Discussions regarding over-medicating with 
these patients revealed that most believed it would improve 
their results upon intraocular pressure (IOP) measurement. It 
is also possible that, in some of these patients, the lever was 
depressed multiple times during transport to clinic. None of 
the patients included in this review were 100% adherent to 
the prescribed regimen of drop therapy.
Discussion
The issue of poor adherence to prescribed medication regimens 
crosses into all ﬁ  elds of medicine. A meta-analysis of 569 
studies across multiple specialties found an average nonad-
herence rate of 25% (DiMatteo 2004). Chronic diseases that 
are asymptomatic in their early stages, such as diabetes and 
hypertension, often are accompanied by patient nonadher-
ence to prescribed medication regimens (Degli Esposti et al 
2002a, 2002b; Hertz et al 2005). Glaucoma is a chronic disease 
similar to these, in that initially, the patient does not note any 
symptoms and is less likely to be concerned with taking medi-
cations if not properly motivated (Zimmerman and Zalta 1983; Clinical Ophthalmology 2007:1(1) 81
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Weinreb 1992; Tsai et al 2003). The majority of patients with 
glaucoma are managed initially with medical therapy, which 
has been proven to prevent or delay progression of nerve ﬁ  ber 
layer loss and visual ﬁ  eld deterioration (Kass et al 2002). This 
highlights the importance of studying patient compliance and 
adherence to better understand how to improve quality of care 
and decrease the chance of disease progression.
One unique problem with glaucoma therapy is the difﬁ  culty 
that some individuals have with instilling eye drops into their 
own eyes. There have been multiple reports on devices that 
assist the patient in instillation of drops as well as instruments 
which monitor and record compliance data. Assistive devices 
are particularly useful in patients who suffer with dexterity 
problems or arthritis. Several devices, such as the Easidrop® 
(Vidcom Marketing, London, UK), Owen-Mumford Auto-
drop® (Marietta, GA), and Opticare® (Cameron-Graham 
Ltd., Huddersﬁ  eld, UK), have been designed to help patients 
with proper drop installation and have been met with varying 
degrees of success (Rivers 1992). The design of many glau-
coma drop bottles, often slender and small, makes it harder 
for some elderly patients to grasp and squeeze in a controlled 
manner. The lever design of the TDA may allow for some 
patients to overcome dexterity and/or strength limitations that 
effect their ability to instill eye medications.
Electronic monitoring of eye drops is currently viewed 
as the most objective, albeit indirect, measure of a patient’s 
adherence to their medical regimen (Schwartz 2005). Past 
attempts at electronic monitoring included the develop-
ment of an eye drop medication monitor that electronically 
recorded the date and time of each drop administration over 
a six-week period (Kass et al 1984). An electronic time 
stamp was recorded when the cap was removed followed 
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Figure 1 The TravatanTM Dosing Aid printout is divided in to three columns that include date, time, and number of lever depressions. In this case, the patient appears to 





















Figure 2 Mean days missed for those dosing travoprost in the morning (3.33 ± 1.33) compared with evening (5.87 ± 1.52) were statistically signiﬁ  cant (p < 0.001).Clinical Ophthalmology 2007:1(1) 82
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by inversion of the bottle. The electronic attachment, housed 
inside the bottle, was found to monitor accurately when tested 
against known medication regimens. The data collecting 
accuracy of the dosing device used in the current study has 
been validated, both through published studies and within 
our own clinical experience, and appears to be accurate and 
consistent in measuring drop installation when used correctly 
(Boden et al 2006; Friedman et al 2007).
A study by Laster and colleagues (1996) investigated 
the use of an electronic medication alarm device (Prescript 
TimeCapTM, Wheaton Medical Technologies, Inc., Millville, 
NJ) to enhance compliance in glaucoma patients. Thirteen 
patients, all on pilocarpine, were selected for the study and 
followed for a period of time while using the alarm device 
and when not using the device. They estimated compliance by 
the amount of pilocarpine used and by patient questionnaire. 
They found that, while using the alarm device, patients were 
more likely to take their medication as measured by amount 
of pilocarpine used. In addition, all participants reported that 
the alarm device helped them remember to take their medica-
tion and was easy to use. The investigators concluded that the 
alarm device was useful in improving compliance.
Another commonly cited reason for noncompliance is 
the difﬁ  culty of remembering to use drops at night prior to 
sleeping. Many of our patients have complained that they fall 















Figure 3 Mean percent adherence of morning (82.72 ± 7.32) and evening (78.96 ± 6.12) dosing groups were similar (p = 0.08).
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Figure 4 TravatanTM Dosing Aid printout revealing nonadherence (as marked by each star) in a patient who appears to have overmedicated on the day of examination by 
taking six drops. Clinical Ophthalmology 2007:1(1) 83
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nighttime dosing regimen. Several of our patients work late 
shifts and ﬁ  nd it difﬁ  cult to place drops in during work hours. 
For these patients, we often recommend morning dosing 
in association with a commonly held ritual such as eating 
breakfast or brushing teeth. The current study was designed 
to identify any differences in compliance between patients 
who take their drops in the evening versus those who take 
drops in the morning.
Once concern about morning dosing is that the prosta-
glandin analogs may be less effective compared with evening 
dosing. Konstas and colleagues (2006) studied this question 
and found that both morning and evening dosing of travoprost 
provided effective 24-hour IOP control, with evening dosing 
of travoprost demonstrating slightly greater daytime efﬁ  cacy 
and a narrower range of 24-hour pressure while mean IOP 
was essentially the same in both groups. Although diurnal 
ﬂ  uctuations do appear to be slightly less with evening dosing 
in a controlled study situation, this difference is irrelevant 
if a patient fails to take the medication as prescribed due to 
external factors such as lifestyle or working hours. 
The electronic time stamp data in the current study 
demonstrates that patients using travoprost once daily in 
the morning tended to be more likely to remain adherent 
to prescribed medical regimen compared with a cohort of 
patients taking the same medication at night. While the dif-
ference in adherence was not statistically signiﬁ  cant, it does 
highlight two important facts. First, patients appear to have 
an equal chance of being adherent to drop therapy regardless 
of time of administration. Second, it is important to address 
patient needs through discussion and written instructions to 
better plan therapeutic regimens to ﬁ  t within individual daily 
routines (Kharod et al 2006). Those who took their drops in 
the morning were less likely to be nonadherent due to miss-
ing a drop while slightly more likely to be nonadherent due 
to taking the drop at a later time than preprogrammed in to 
the TDA. This issue could be remedied by altering dosing 
regimens even further based on real world dosing data.
Finally, the adherence rate in both groups in this study 
was near 80%. This value is higher than those reported in 
previous manuscripts dealing with adherence in glaucoma 
therapy. This may indicate that the use of the TDA improves 
adherence to medical therapy by fulﬁ  lling its intended role 
as both a dosing aid and adherence device regardless of dos-
ing time. Further testing is needed in a prospective manner 
to investigate the long-term effect of dosing aids on patient 
eye drop administration habits and potential impact on 
therapeutic outcomes. 
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